Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 24, 2015. The document serves as a regulatory update regarding a strategic partnership with Theravance, Inc. concerning the respiratory drug Relvar Ellipta (fluticasone furoate/vilanterol).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a regulatory announcement rather than a financial results report.
Material Changes and Developments
- Regulatory Filing: GSK and Theravance announced the intention to file a supplemental Japanese New Drug Application (sJNDA) for Relvar Ellipta for the treatment of chronic obstructive pulmonary disease (COPD) in Japan during the first quarter of 2016.
- Clinical Study Results: The decision follows Study 200820, a global phase III study involving 1,620 patients (370 from Japan). Results showed that patients receiving FF/VI 100/25mcg achieved a statistically significant improvement in lung function (trough FEV1) compared to vilanterol (VI) 25mcg alone at 12 weeks (p=0.001).
- Safety Profile: The most frequently reported adverse events (≥3%) were nasopharyngitis, COPD exacerbation, and headache. Pneumonia was reported in less than 1% of subjects in each group.
Guidance, Outlook, and Risks
Outlook: The companies anticipate filing the sJNDA in Q1 2016. Full study results are expected to be published or presented in the future.
Risks and Contingencies:
- Forward-Looking Statements: Both GSK and Theravance caution that projections regarding regulatory approval, commercial plans, and financial returns are subject to risks and uncertainties that may cause actual results to differ materially.
- Safety Warnings: The filing includes extensive Important Safety Information (ISI) for the US market, noting that Long-acting beta 2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Other risks include pneumonia (some fatal), adrenal insufficiency, cardiovascular effects, and hypersensitivity reactions.
- Operational Risks: Theravance highlights risks related to the transition period following its spin-off, potential delays in clinical studies, and dependence on third-party collaborators.
Investor Verification Checklist
- Verify the timeline for the submission of the sJNDA in Japan (targeted for Q1 2016).
- Monitor the Japanese Ministry of Health, Labour and Welfare (MHLW) for approval status of Relvar Ellipta for COPD.
- Review upcoming publications or presentations regarding the full results of Study 200820.
- Assess the potential impact of regulatory approval on royalty revenue streams for Theravance and sales for GSK.
- Confirm that no new safety signals have emerged since the filing date that would alter the risk profile of the drug.